Update - Vitalograph Brexit Statement

06 Apr 2020

As of 31st January, 2020, Britain left the EU with a fully ratified agreement, with no change to current trade agreements during a period of negotiation to the end of 2020.

Negotiations were scheduled to take place from March 2020, but have been put on hold to allow both the UK and EU authorities to focus on dealing with the COVID-19 pandemic. Vitalograph will maintain their Brexit contingency planning initiative during this negotiation period, directed by our Business Continuity Planning (BCP) group to identify, address and mitigate potential risks to continuity of the supply of products and services. The ever-changing situation will continue to be reviewed on a regular basis and to ensure all the main potential risks have been identified and addressed as far as possible under the current circumstances.

The following actions have been taken to mitigate the impact of Brexit:

  • Full review & re-stock where necessary in our UK and German warehouses to counteract any shipping delays.
  • EORI registration in place to mitigate custom’s issues with import/export between EU and UK sites.
  • Transfer of notified body from the British Standards Institution (BSI) UK to BSI NL to ensure validity of CE registration post Brexit.
  • We are continually reviewing MHRA guidance for the import of Medical Devices from the EU to UK. Based on current available information we can meet their requirements.

New actions will be added as the future trade and regulatory arrangements become clearer.

Please note that Vitalograph has business operations located in multiple, diverse countries with critical suppliers multi-sourced from different geographies.

Terms and Conditions © Vitalograph 2011 - 2020